Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Big Pharma moving to checkpoint inhibitors to fight cancer. We are about to receive a patent to treat checkpoint inhibitor pneumonitis a common occurrence in patients receiving this therapy. Connect the dots. Aviptadil for CIP will be huge.

On Feb. 28, the FDA accepted Bristol Myers Squibb’s application for approval of a new use of blockbuster checkpoint inhibitor Opdivo and said it would make a decision by July 13.

That estimate turned out to be conservative, to say the least. On Friday, just five days after accepting the application, the FDA OK’d it, handing the Big Pharma a landmark approval.

Opdivo can now be used to treat patients with early-stage non-small cell lung cancer prior to receiving surgery to remove their tumor.

~Wong, Y@h00 RLFTF financial conversations

==================================
By acquiring the rights to AdVita’s therapy formulation, Relief also will accelerate and secure RLF-100’s future development as an inhaled therapy for lung diseases, such as pulmonary sarcoidosis, that are associated with COVID-19. Other lung diseases associated with COVID-19, which also could potentially be treated by RLF-100, include checkpoint inhibitor-induced pneumonitis, and acute respiratory distress syndrome (ARDS).

https://sarcoidosisnews.com/2021/01/28/deal-gives-relief-therapeutics-intellectual-rights-potential-sarcoidosis-therapy-rlf-100/